CDK12 and Familial prostate cancer: Recently, in prostate cancer, CDK12 biallelic inactivating mutation was significantly correlated with T cells infiltration and identified a novel subtype of metastatic castration-resistant prostate cancer with high sensitivity to immune checkpoint inhibition8.